This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

AstraZeneca And The Medicines Company Announce Global Collaboration In Acute Ischemic Heart Disease

Stocks in this article: AZN MDCO

AstraZeneca (NYSE: AZN) and The Medicines Company (NASDAQ: MDCO) announced today a global collaboration for acute ischemic heart disease compounds. The first part of this collaboration is a US co-promotion for AstraZeneca’s oral antiplatelet medicine BRILINTA ® (ticagrelor) tablets. Under the terms of the co-promotion agreement, The Medicines Company sales force will begin supporting BRILINTA in May 2012. This will complement the AstraZeneca sales team’s promotion of BRILINTA to US hospital customers and practitioners whose patients with acute coronary syndrome (ACS) may benefit from this important therapy.

“The Medicines Company is a respected organization with a strong network in interventional cardiology," said Lisa Schoenberg, Vice President, US Sales and Marketing, Growth Portfolio, AstraZeneca. “We have laid the groundwork for BRILINTA in the US with strong managed market access as well as hospital formulary and protocol access such that now is the right time to bring this important medicine to more patients with ACS through additional support in the acute setting.”

Under the terms of the global collaboration, a joint development committee and a joint commercialization committee have been established to prepare and deliver global development and commercialization plans related to AstraZeneca’s BRILINTA and The Medicines Company’s Angiomax ® (bivalirudin) for injection and cangrelor, which is in development as an acute intravenous antiplatelet agent. Implementation of these plans is subject to further agreements between both parties.

The agreement also outlines terms for the four-year US BRILINTA co-promotion agreement in which AstraZeneca will pay The Medicines Company $15 million per year for performing pre-agreed commercialization activities with up to an additional $5 million per year paid if performance thresholds are met.

“Our goal in joining this global collaboration with AstraZeneca is to help improve patient care with a comprehensive suite of solutions for acute ischemic heart disease,” said Brent Furse, Senior Vice President and Chief Customer Officer of The Medicines Company. “This opportunity aligns with our vision to lead in acute, intensive care hospital medicine globally.”

1 of 7

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs